10Oct/13

From 2012 to 2022, the Rheumatoid Arthritis Market Will Grow Moderately … – The Providence Journal

From 2012 to 2022, the Rheumatoid Arthritis Market Will Grow Moderately
The Providence Journal
Pfizer/Takeda’s Jak inhibitor Xeljanz will likely be used after the TNF-alpha inhibitors initially, competing with Bristol-Myers Squibb/Ono Pharmaceutical’s Orencia, rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo’s Rituxan, Roche’s MabThera) and 

and more »